Cinqair (reslizumab) approved for treatment of severe asthma

FDA approves new miracle treatment for asthma

The U.S. Food and Drug Administration has approved reslizumab, which will be sold under the name Cinqair, as a treatment for severe asthma in patients aged 18 and above.

The drug, made by Teva Pharmaceuticals, should be administered by a medical professional in a clinical setting. Records from the Centers for Disease Control and Prevention (CDC) show that as of 2013, over 22 million Americas suffer from the disease, and over 400,000 asthma-related hospitalizations occur each year.

The product was tested in 4 double-blind, randomized, placebo-controlled trials involving patients with severe asthma who received either Cinqair or placebo every 4 weeks as an add-on therapy.

Such move allows asthmatic patients who have a history of severe attacks to have another supportive drug despite taking other existing therapies. Cinqair is manufactured by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells.

The patients received either Cinqair or placebo every four weeks as supplementary asthma treatment.

Compared with placebo, patients with severe asthma receiving Cinqair had fewer asthma attacks, and a longer time to the first attack.

Nucala was approved by the FDA in November and, like Cinqair, is an antibody that reduces levels of eosinophils, a type of white blood cell that contributes to the development of asthma.

The FDA warned, however, that Cinqair could cause severe allergic-like reactions that could kill the patient. There are some side effects, however, that may be life-threatening, including cancer and muscle pain.

Upon commercial availability of CINQAIR®, Teva will launch Teva Support Solutions, a comprehensive program that will provide personalized support, training and education to healthcare providers and patients who have been prescribed CINQAIR.